#Rukobia

FDA Approves Rukobia for People With Multidrug-Resistant HIV

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

ViiV applies for FDA approval of HIV drug fostemsavir

The attachment inhibitor performed well as an adjunct to an optimized antiretroviral regimen among those with multidrug-resistant HIV.

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.